FDA/CDC

FDA approves Wegovy (semaglutide) for obesity in teens 12 and up


 

The Food and Drug Administration has approved semaglutide 2.4 mg (Wegovy), a once-weekly subcutaneous injection, for the additional indication of treating obesity in adolescents aged 12 years and older.

This is defined as those with an initial body mass index at or above the 95th percentile for age and sex (based on CDC growth charts). Semaglutide must be administered along with lifestyle intervention of a reduced calorie meal plan and increased physical activity.

A stamp saying "FDA approved." Olivier Le Moal/Getty Images

When Wegovy was approved for use in adults with obesity in June 2021, it was labeled a “game changer.”

The new approval is based on the results of the STEP TEENS phase 3 trial of once-weekly 2.4 mg of semaglutide in adolescents 12- to <18 years old with obesity, the drug’s manufacturer, Novo Nordisk, announced in a press release.

In STEP TEENS, reported at Obesity Week 2022 in November, and simultaneously published in the New England Journal of Medicine, adolescents with obesity treated with semaglutide for 68 weeks had a 16.1% reduction in BMI compared with a 0.6% increase in BMI in those receiving placebo. Both groups also received lifestyle intervention. Mean weight loss was 15.3 kg (33.7 pounds) among teens on semaglutide, while those on placebo gained 2.4 kg (5.3 pounds).

At the time, Claudia K. Fox, MD, MPH, codirector of the Center for Pediatric Obesity Medicine at the University of Minnesota – who was not involved with the research – told this news organization the results were “mind-blowing ... we are getting close to bariatric surgery results” in these adolescent patients with obesity.

Semaglutide is a GLP-1 agonist, as is a related agent, also from Novo Nordisk, liraglutide (Saxenda), a daily subcutaneous injection, which was approved for use in adolescents aged 12 and older in December 2020. Wegovy is the first weekly subcutaneous injection approved for use in adolescents.

Other agents approved for obesity in those older than 12 in the United States include the combination phentermine and topiramate extended-release capsules (Qsymia) in June 2022, and orlistat (Alli). Phentermine is approved for those aged 16 and older.

A version of this article first appeared on Medscape.com.

Recommended Reading

Will ICER review aid bid for Medicare to pay for obesity drugs?
MDedge Cardiology
Both potatoes and beans reduced insulin resistance, weight in controlled study
MDedge Cardiology
The TikTok trend that triggered a diabetes drug shortage
MDedge Cardiology
Green Mediterranean diet lowers visceral adipose tissue
MDedge Cardiology
Everyone wins when losers get paid
MDedge Cardiology
Cold water immersion can have benefits
MDedge Cardiology
Low-carb, high-fat, calorie-unrestricted diet improves type 2 diabetes
MDedge Cardiology
Does paying people to lose weight work?
MDedge Cardiology
Bite-sized bouts of exercise: Why they are valuable and what they are missing
MDedge Cardiology
‘The Whale’: Is this new movie fat-phobic or fat-friendly?
MDedge Cardiology